Back to Nasal Cavity Squamous Cell Carcinoma

Nasal Cavity Squamous Cell Carcinoma — Clinical Trials

MONDO:00060593 active·2 recruitingLast updated: Mar 20, 2026, 3:40 PM

Trial Landscape

Nasal Cavity Squamous Cell Carcinoma has an emerging clinical trial program, driven by procedure and drug treatment.

Recruiting

Active Trials

By Approach

Procedure3

Drug Treatment2

Biological Therapy2

By Phase

Phase 1

Phase 2

Phase 3

Sponsor Types

NIH3

Trial Locations

United States3 trials

Canada1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

3 Trials

Phase 2Recruiting

NCT06980038

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Aug 2026Est. completion: Nov 2027Updated: Mar 2026

Phase 1Recruiting

NCT05172245

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2022Est. completion: Jun 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT05063552

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2023Est. completion: Dec 2027Updated: Mar 2026

Stay informed about clinical trials for Nasal Cavity Squamous Cell Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 3:40 PM

Nasal Cavity Squamous Cell Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Trial Locations

3 Trials

Open Trials2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Active Trials1

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers